Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal ad...
New panel expands coverage for Alzheimer’s and Parkinson’s diseases including 15 new biomarkers developed with support from The Michael J. Fo...
- Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study - The enhanced immunosu...
-Johnson & Johnson announced the arrival in Peru of a new pulsed field ablation (PFA) technology for the treatment of drug-refractory paroxysmal atri...
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery...
In this BioPharma Boardroom interview, Steven Quay, Founder and CEO of Atossa Therapeutics, outlines the scientific rationale behind developing (Z)-endoxif...
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administrati...
The company also announced a strategic investment from Leonardo DiCaprio ImmunoScape Pte. Ltd., an A*STAR spin-out backed by Amgen Ventures an...
Allosteric Bioscience, Inc. is utilizing Genetics, Genomics, Systems Biology, Quantum Computing, Advanced Proprietary AI and Proprietary Molecular ...
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron che...
The Progeria Research Foundation (“PRF”), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gi...
Beginning a new drug discovery collaboration using Congruence’s globally recognized Revenir™ platform for the creation of small molecule ...
Meiji Seika Pharma Co., Ltd. announced that morcamilast (proposed international nonproprietary name; development code: ME3183), a selective phosphodieste...
© 2026 Biopharma Boardroom. All Rights Reserved.
